Zejula (niraparib) given in combination with Avastin (bevacizumab) shows promising safety and efficacy at delaying disease progression in women with advanced ovarian cancer who had responded to a first-line platinum-based chemotherapy plus Avastin, interim results from a Phase 2 trial show. These findings are in the presentation, “Phase II OVARIO study of niraparib bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab,” for the May 14 webinar as part of the Society of Gynecologic Oncology…
May 14, 2020May 14, 2020